An Observational Study of First-Line Bevacizumab (Avastin) With Fluoropyrimidine-Based Chemotherapy in Participants With Metastatic Colorectal Cancer

Sponsor
Hoffmann-La Roche
Study ID
NCT01712347
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab — DRUG
    Bevacizumab will be administered as per approved label.
  • Chemotherapy — DRUG
    The protocol does not specify the chemotherapy regimen to be used, the choice of chemotherapy will be at the discretion of treating physician.

Study Details

This multicenter observational study will evaluate the efficacy and safety of first-line bevacizumab (Avastin) in combination with fluoropyrimidine-based chemotherapy in participants with metastatic colorectal cancer (mCRC). Participants for whom the treating physician has decided to initiate first-line fluoropyrimidine based chemotherapy in combination with bevacizumab will be observed for approximately 4 years.

Key Dates

First listed
Oct 23, 2012
Start date
Oct 11, 2012
Status verified
Jun 2017
Primary completion
Jul 1, 2016
Completion
Jul 1, 2016

Study Design

Enrollment
351 participants (actual)

Arms

  • Arm: mCRC Participants
    mCRC participant will receive bevacizumab as per approved label with the approved first-line fluoropyrimidine based chemotherapy, as per physician discretion. The protocol does not specify the chemotherapy regimen to be used, the choice of chemotherapy will be at the discretion of treating physician.

Primary Outcome Measure

Overall survival from the time of starting first-line therapy [ Time Frame: Start of first line therapy until death (up to approximately 4 years) ]

Related Studies